Administration description

National Oceanic and Atmospheric Administration, description of Manganese Nodule ProcessingMctivitiesfor Environmental Studies, 3 Vols., NTlS, Springfield, Va., 1977, PB-274 913, PB-274 914, PB-274 915. 

Description of the processes where chemicals are used that might qualify for Chemical Leasing projects (general technical, organisational and administrative description) — short list of industrial processes. 

Commercial Item Description (CID), Sodium Chloride, Technical (Water) Conditioning Grade A-A-694 General Services Administration... 

Before administration of an otic preparation, the primary health care provider examines the ear and external structures surrounding the ear and prescribes the drug indicated to treat the disorder. The nurse may be responsible for examining the outer structures of the ear, namely the earlobe and the skin around the ear. The nurse documents a description of any drainage or the presence of impacted cerumen. 

Name and description of the investigational product(s). A summary of findings from non-clinical sfudies and from clinioal trials that is relevant to the trial. Summary of the known and potential risks and benefits, if any, to human subjects. Description of and justification for the route of administration, dosage, dosage regimen, and treatment period(s). A statement that the trial will be conducted in compliance with the protocol, GCP and the applicable regulatory requirement(s). Description of the population to be studied. References to literature and data that are relevant to the trial, and that provide background for the trial... 

Wood RW, Grubman J, Weiss B Nitrous oxide self-administration by the squirrel monkey. J Pharmacol Exp Ther 202 491 99, 1977 Wood RW, Coleman JB, Schuler R, et al Anticonvulsant and antipunishment effects of toluene. J Pharmacol Exp Ther 230 407 12, 1984 World Health Organization The lCD-10 Classification of Mental and Behavioural Disorders Clinical Descriptions and Diagnostic Guidelines. Geneva, World Health Organization, 1992... 

Despite the evidence for the cytotoxicity of CNTs, there are an increasing number of published studies that support the potential development of CNT-based biomaterials for tissue regeneration (e.g., neuronal substrates [143] and orthopedic materials [154—156]), cancer treatment [157], and drug/vaccine delivery systems [158, 159]. Most of these applications will involve the implantation and/or administration of such materials into patients as for any therapeutic or diagnostic agent used, the toxic potential of the CNTs must be evaluated in relation to their potential benefits [160]. For this reason, detailed investigations of the interactions between CNTs/CNT-based implants and various cell types have been carried out [154, 155, 161]. A comprehensive description of such results, however, is beyond the scope of this chapter. Extensive reviews on the biocompatibility of implantable CNT composite materials [21, 143, 162] and of CNT drug-delivery systems [162] are available. 

Many technicians may not be famihar with terms such as sublingual (under the tongue), buccal (between the cheek and gingiva), otic, and so on. A clear description of each of these nontraditional routes (i.e., other than gavage routes) should be discussed with technicians, and instructions may also be written down and given to them. Demonstrations are often useftd to illustrate selected techniques of administration (e.g., to use an inhaler or nebulizer). Some chemicals must be placed by technicians into body orifices (e.g., medicated intrauterine devices such as Proges-terset). 

Name and description of the clinical trial protocol Summary of results from nonclinical studies Potential risks and benefits to human subjects Description and justification for route of administration, dosage, and treatment plan Compliance to GCP... 

Food and Drug Administration. Guidance for Industry, Content and Format of Chemistry, Manufacturing and Controls Information and Establishment Description Information for a Vaccine or Related Product, FDA, Rockville, MD, 1999. 

As great administrators, the Romans instituted hospitals, although these were used mainly to cater to the needs of the military. Through this work, organized medical care was made available. The Romans also extended the pharmacy practice of the Greeks. Dioscorides and Galen were two noted physicians in Roman days. Dioscorides s Materia Medica contains descriptions of treatments based on 80% plant, 10% animal, and 10% mineral products. 

This was the first documented study of exposure of a military volunteer to a threshold dose of both i.m. BZ and oral LSD, given together. It included a careful baseline for each measurement used. Clinical observations were scheduled at 1, 2, 3, 4, 5, 6, 10, 24, 48 and 72 hours after administration of drug. Vital signs and neurological status were recorded at approximately the same intervals. The examining physician frequently documented mental status. These data were less than optimal due to the relative infrequency of observations and the sparseness of behavioral descriptions. Even in combination, the doses used were too small to cause more than minimal effects. 

The SLC document typically consists of technical documents with system descriptions. It also has references to standard operating procedures (SOPs) and administrative and maintenance systems. A completed SLC documentation set is typically required prior to using analyzer systems in the pharmaceutical laboratory or manufacturing site. It is also required prior to use of the data obtained by the system in GMP. 

Figure 7 shows the effect of ectopic administration of T3 to the developing zebrafish embryo. At nontoxic concentration (50 nM), only a moderate fraction (less than 5%) of the zebrafish transcriptome shows significant changes. Ossification, visual processes, and the hematopoietic system were the physiological processes most affected by the treatment, in a pattern consistent with an advancement of the development in these particular functions (Fig. 7b). Genes involved in these three processes are known targets for TDCs during metamorphosis in amphibians, teleost fishes, and lampreys [54—60], and constitute molecular counterparts of different endpoints used to test for TDC in amphibians [56, 58]. Therefore, they are excellent candidates for markers of thyroid disruptors in zebrafish at early developmental stages. Chapter 14 provides a more in-deep description of the developmental effects of thyroid disruption in zebrafish embryos.

If after single dose administration, the blood samples are not collected at time intervals, which allow for a description of the whole plasma concentration time course, including the absorption, distribution, and elimination phase, the information obtained is limited. In particular, data should be available in the hrst hours after administration to cover the absorption phase. If measurements of the parent compound and its metabolite(s) are made in this period, this will allow assessment of an extensive first pass effect, i.e., when a substance after oral administration is transported via the portal vein to the liver where metabolism takes place before the substance enters the systemic circulation. 

---